Study of Mapatumumab in Combination With Bortezomib (Velcade) and Bortezomib Alone in Subjects With Relapsed or Refractory Multiple Myeloma

Inclusion Criteria:

Diagnosed with multiple myeloma that is refractory or has relapsed after treatment
Measurable serum and/or urine M-protein
Failed 1 or 2 prior therapies for multiple myeloma
18 years of age or older

Exclusion Criteria:

Received more than 2 prior therapies for multiple myeloma.
Previous cancer therapies (chemotherapy, biologic therapy, radiation therapy or immunosuppressants) within the last 3 weeks
Received monoclonal antibodies within the last 3 weeks (chimeric or murine) or 8 weeks (human or humanized)
Received investigational (not yet approved by a regulatory authority) agent to treat multiple myeloma within the last 4 weeks
Subjects who received a stem cell transplant using cells from themselves in the past 16 weeks
Subjects who received a stem cell transplant using cells from another individual
Previously treated with bortezomib or mapatumumab
Known HIV, hepatitis-B, hepatitis-C, or hepatitis A infection
Infection requiring antibiotics or hospitalization within the last 2 weeks
Major surgery within the last 4 weeks
Diagnosis with POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes)
History of other cancers within the past 5 years
Pregnant or breast-feeding women